Obesity / Overweight | Unmet Need | US/EU | 2021

Obesity is a significant public health concern in the United States and Europe. Its chronic progression is associated with type 2 diabetes and adverse cardiovascular (CV) health. Following a series of high-profile market withdrawals, the obesity drug landscape has seen several new treatments launch since 2012, but uptake of these agents has been slow, suggesting suboptimal risk-benefit profiles and reflecting the poor reimbursement environment for prescription weight-loss agents. In this report, endocrinologists compare current antiobesity drugs and discuss the attributes that the next generation of drugs should have to serve this medically important population and to succeed commercially in a potentially lucrative market.


  • How do endocrinologists rate current antiobesity drugs, such as Novo Nordisk’s Saxenda?
  • What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • What trade-offs across different clinical attributes and prices are needed from new obesity drugs in order to be preferred by endocrinologists?
  • How can less-frequent dosing, route of administration, CV and renal benefit, and efficacy influence physician preference?


Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with the United States and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European endocrinologists fielded in February 2021

Key companies: Novo Nordisk, Vivus, Currax Pharmaceuticals, Orexigen Therapeutics

Key drugs: Saxenda, Qsymia, Contrave/Mysimba, Xenical, phentermine

Login to access report